Qiagen (QGEN) Set to Announce Quarterly Earnings on Monday

Qiagen (NYSE:QGEN) is set to release its earnings data after the market closes on Monday, April 29th. Analysts expect Qiagen to post earnings of $0.44 per share for the quarter. Qiagen has set its FY 2024 guidance at 2.100- EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. The firm had revenue of $509.00 million for the quarter, compared to the consensus estimate of $500.77 million. Qiagen had a net margin of 17.37% and a return on equity of 12.99%. During the same period in the previous year, the firm posted $0.53 earnings per share. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Stock Performance

QGEN stock opened at $41.65 on Friday. The company has a quick ratio of 1.62, a current ratio of 1.99 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $9.50 billion, a price-to-earnings ratio of 27.53, a P/E/G ratio of 3.50 and a beta of 0.41. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.70. The firm has a 50 day moving average of $42.61 and a two-hundred day moving average of $42.66.

Wall Street Analyst Weigh In

Several analysts have commented on QGEN shares. Citigroup decreased their target price on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. JPMorgan Chase & Co. boosted their target price on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, February 8th. Finally, Morgan Stanley raised shares of Qiagen from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $49.48 to $51.00 in a research report on Friday, February 16th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.69.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.